Patient characteristics
| Patients . | Age, y . | Disease . | Conditioning regimen . | GVHD prophylaxis . | HLA match of cord to patient . | Donor CD3 chimerism, <d 30 . |
|---|---|---|---|---|---|---|
| CMV positive | ||||||
| 1 | 11 | AML | Flu, Cy, TBI 14.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB2 |
| 2 | 56 | AML | Flu, Cy, TBI 200 cGy | CsA, MMF | 5/6, 4/6 | 100% CB2 |
| 3 | 30 | AML | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 5/6, 4/6 | 100% CB2 |
| 4 | 14 | ALL | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 5/6, 4/6 | 100% CB1 |
| 5 | 17 | T-ALL | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB2 |
| 6 | 14 | CML | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB2 |
| 7 | 46 | AML | Flu, Treo, TBI 200 cGy | CsA, MMF | 4/6, 4/6 | 100% CB1* |
| 8 | 13 | T-ALL | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 5/6, 4/6 | 98% CB1, 2% host† |
| 9 | 33 | AML | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB2 |
| 10 | 29 | AML | Flu, Cy, TBI 200 cGy | CsA, MMF | 4/6, 4/6 | Mixed CB1/2, 0% host‡ |
| 11 | 26 | AML | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 5/6, 4/6 | 100% CB2 |
| 12 | 4 | AML | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB2 |
| 13 | 38 | MDS | Flu, Treo, TBI 200 cGy | CsA, MMF | 4/6, 4/6 | 100% CB1 |
| 14 | 73 | Pro-T-ALL | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 5/6, 4/6 | Mixed CB1/2, host§ |
| 15 | 33 | AML | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB1|| |
| CMV negative | ||||||
| 16 | 56 | AML | Flu, Treo, TBI 200 cGy | CsA, MMF | 5/6, 4/6 | 91% CB1¶ |
| 17 | 39 | AML | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB1 |
| 18 | 26 | Biphenotypic AL | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB1 |
| 19 | 21 | ALL | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB1 |
| Patients . | Age, y . | Disease . | Conditioning regimen . | GVHD prophylaxis . | HLA match of cord to patient . | Donor CD3 chimerism, <d 30 . |
|---|---|---|---|---|---|---|
| CMV positive | ||||||
| 1 | 11 | AML | Flu, Cy, TBI 14.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB2 |
| 2 | 56 | AML | Flu, Cy, TBI 200 cGy | CsA, MMF | 5/6, 4/6 | 100% CB2 |
| 3 | 30 | AML | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 5/6, 4/6 | 100% CB2 |
| 4 | 14 | ALL | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 5/6, 4/6 | 100% CB1 |
| 5 | 17 | T-ALL | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB2 |
| 6 | 14 | CML | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB2 |
| 7 | 46 | AML | Flu, Treo, TBI 200 cGy | CsA, MMF | 4/6, 4/6 | 100% CB1* |
| 8 | 13 | T-ALL | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 5/6, 4/6 | 98% CB1, 2% host† |
| 9 | 33 | AML | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB2 |
| 10 | 29 | AML | Flu, Cy, TBI 200 cGy | CsA, MMF | 4/6, 4/6 | Mixed CB1/2, 0% host‡ |
| 11 | 26 | AML | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 5/6, 4/6 | 100% CB2 |
| 12 | 4 | AML | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB2 |
| 13 | 38 | MDS | Flu, Treo, TBI 200 cGy | CsA, MMF | 4/6, 4/6 | 100% CB1 |
| 14 | 73 | Pro-T-ALL | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 5/6, 4/6 | Mixed CB1/2, host§ |
| 15 | 33 | AML | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB1|| |
| CMV negative | ||||||
| 16 | 56 | AML | Flu, Treo, TBI 200 cGy | CsA, MMF | 5/6, 4/6 | 91% CB1¶ |
| 17 | 39 | AML | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB1 |
| 18 | 26 | Biphenotypic AL | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB1 |
| 19 | 21 | ALL | Flu, Cy, TBI 13.2 Gy | CsA, MMF | 4/6, 4/6 | 100% CB1 |
AL, acute leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CB, cord blood donor; CML, chronic myeloid leukemia; CsA, cyclosporine A; Cy, cyclophosphamide; Flu, fludarabine; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; TBI, total body irradiation; Treo, treosulfan.
*2% host at d 56 and d 83, 100% CB1 at d 176; †100% CB1 at d 365; ‡100% mixed CB1/2 >d 165; §0% host d 84; ‖2% host d 80, ¶mixed CB1/2 >d 30, 100% CB1 at d 328.